Charles Schwab
CGON icon

Charles Schwab’s CG Oncology CGON Stock Holding History

Charles Schwab’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.6M Buy
627,185
+84,807
+16% +$5.54M 0.01% 1330
2026
Q1 		$36.7M Sell
542,378
-317
-0.1% -$18K 0.01% 1363
2025
Q4 		$22.5M Buy
542,695
+17,177
+3% +$711K ﹤0.01% 1677
2025
Q3 		$21.2M Buy
525,518
+75,222
+17% +$2.19M ﹤0.01% 1701
2025
Q2 		$11.7M Buy
450,296
+11,018
+3% +$266K ﹤0.01% 1934
2025
Q1 		$10.8M Buy
439,278
+11,518
+3% +$324K ﹤0.01% 1919
2024
Q4 		$12.3M Buy
427,760
+48,096
+13% +$1.65M ﹤0.01% 1923
2024
Q3 		$14.3M Buy
379,664
+202,262
+114% +$7.09M ﹤0.01% 1867
2024
Q2 		$5.6M Buy
177,402
+8,050
+5% +$279K ﹤0.01% 2309
2024
Q1 		$7.43M Buy
+169,352
New +$6.92M ﹤0.01% 2134

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's CGON Position: Q2 2026 in Review

Charles Schwab increased its CG Oncology (CGON) stake by 16% in Q2 2026, buying an estimated $5.54M and bringing the position to 627,185 shares worth $44.6M. The position accounts for 0.01% of the portfolio, ranked #1330.

Charles Schwab first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Charles Schwab held 627,185 shares of CG Oncology worth $44.6M as of Q2 2026.
  • Charles Schwab bought 84,807 CG Oncology shares in Q2 2026, an estimated $5.54M.
  • CG Oncology made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1330 holding.
  • Charles Schwab first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.